Rapamycin: the popular drug for longevity among biohackers
Living longer may be getting easier
Rapamycin is a drug used to suppress the immune system in transplant patients, but scientists have found that it may have another use. The drug has been shown to have anti-aging properties, despite no official research being done on humans as of yet. Researchers are now looking to investigate the drug and determine whether it could be officially employed to treat some of the natural symptoms of aging.
A purpose beyond prescribed
A drug that slows aging probably sounds a lot like science fiction — but it may eventually become a reality. Rapamycin "has gained a large following thanks to longevity researchers and celebrity doctors who, citing animal studies, contend that [it] could be a game changer in the quest to fend off age-related diseases," said The Washington Post. However, the drug has not been officially approved by the Food and Drug Administration as a tool to combat aging. "The agency doesn't consider aging to be a disease, and rapamycin's generic status means there's little financial incentive to run expensive clinical trials to test it on age-related afflictions," said the Post.
This has not stopped biohackers, or people who are looking to expand their lifespan. The drug has shown promise in reducing the symptoms of aging in several species including mice, yeast, dogs and worms. Some scientists say that rapamycin can reduce inflammation "by inhibiting a signaling pathway in the body called mTOR — which seems to be a key regulator of lifespan and aging," said NPR. While rapamycin has yet to be properly tested on humans for anti-aging, people have been prescribed the treatment for this purpose — with seemingly positive, if unaccredited, results. "Anecdotes are no replacement for science," said NPR. "To figure out the risks and benefits of a drug, research is needed."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The next big thing?
Rapamycin is not exactly easy to find. It is a molecule "produced by soil bacteria on the extremely remote Easter Island located in the South Pacific and was initially used for its antifungal properties," said Daily Mail. It was later found to have the immunosuppressant properties for which it is used today. "This exotic molecule, found only on an isolated scrap of land in the middle of the ocean, acts almost like a switch that inhibits a very specific cellular mechanism that exists in nearly everything that lives," said Peter Attia, who runs a medical practice to increase longevity, in his book "Outlive: The Science and Art of Longevity."
While the drug is thought to be helpful to the anti-aging cause in smaller doses, "doctors also caution that no one knows what the optimal dose might be for humans, and taking certain quantities of rapamycin can lead to reproductive harm and insulin resistance as well as making the body more susceptible to infection," said the Post. Since rapamycin is a generic drug, "pharmaceutical companies have little incentive to fund new research," said NPR — thus some scientists are looking to conduct research through grants instead. "The potential is enormous for patients to be able to extend their health span and quality of life as they age," said Daniel Tawfik, the founder of Healthspan, a telehealth service that offers rapamycin for aging and cosmetic purposes, to the Post.
The industry around slowing or preventing aging is growing, with younger and younger advocates joining the cause. Along with rapamycin, "researchers are also working on other drugs that may work in similar ways, and there's a push for new drugs — or other interventions that target biological aging," said NPR.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
Today's political cartoons - December 18, 2024
Cartoons Wednesday's cartoons - thoughts and prayers, pound of flesh, and more
By The Week US Published
-
Honda and Nissan in merger talks
Speed Read The companies are currently Japan's second and third-biggest automakers, respectively
By Peter Weber, The Week US Published
-
Luigi Mangione charged with murder, terrorism
Speed Read Magnione is accused of murdering UnitedHealthcare CEO Brian Thompson
By Peter Weber, The Week US Published
-
The hidden cost of lead exposure on American mental health
Under The Radar Millions of mental health diagnoses have been linked to childhood lead exposure in new study
By Theara Coleman, The Week US Published
-
The growing list of conditions weight-loss drugs could help with
The Explainer Ozempic and similar drugs have been linked to possibly helping diseases beyond diabetes and obesity. Are they miracle drugs?
By Theara Coleman, The Week US Published
-
The great departure: Texas OB-GYNs are leaving the Lone Star State
Under the radar The state is suffering an exodus of health care professionals, creating more maternity care deserts
By Theara Coleman, The Week US Published
-
Mar-a-Lago face: the hottest Maga plastic surgery trend
Under the Radar Trump supporters driven by 'desire to please the President-elect' but phenomenon now 'crossing party line'
By The Week UK Published
-
ADHD drugs shortage: what's behind it?
The Explainer Supply chain issues and 'tripling' of prescriptions concerns GPs as problems getting medication become 'desperate'
By The Week UK Published
-
A growing iodine deficiency could bring back America's goiter
Under the Radar Ailment is back thanks to complacency, changing diets and a lack of public-health education
By Harriet Marsden, The Week UK Published
-
Cannabinoid hyperemesis syndrome: a rare but troubling health risk for cannabis users
The Explainer The illness is sending some chronic marijuana users to emergency care for painful persistent vomiting
By Theara Coleman, The Week US Published
-
No more bugging: how Egypt became certified malaria-free
Under the radar It was a century-long effort
By Devika Rao, The Week US Published